Partnology’s Post

Great news for innovative R&D in the UK and further collaboration with top universities in England. Apollo Therapeutics has raised $226.5 million in a Series C financing which adds to the $195 million previously raised. Apollo are a portfolio biopharmaceutical company. The portfolio-model is built around a centralised management team of capital allocators and functional leaders with deep expertise in pharmaceutical R&D, manufacturing, commercial strategy, fund-raising, and business development, leveraged over a diverse portfolio of therapeutic programs, each led by a dedicated and seasoned asset leader. The Company has a scalable R&D platform for the evergreen discovery and development of new medicines. This is enabled by an unprecedented level of access to five of the world’s leading universities and research institutes. #drugdiscovery #drugdevelopment #researchanddevelopment

Opinion: 2024 Will Be a Buyers’ Market in Biopharma. It Already Is. The sale of listed contract drugmaker Catalent to Novo Nordisk last week follows Johnson & Johnson’s recent agreement to acquire Ambrx Biopharma for $2 billion, Gilead’s $4.3 billion acquisition of CymaBay, BMS’ $4 billion acquisition of Rayzebio, and Pfizer’s $43 billion acquisition of Seagen. Collectively, these transactions illustrate the growing appetite among pharma companies for biotechs that can fill product development pipelines and increase top line revenues, particularly in sectors such as obesity, oncology and immunology. The era of mega deals in the life sciences sector, epitomized by transactions like BMS’s $74 billion acquisition of Celgene in 2019, may be over, but biopharma M&As are once again growing more frequent and more valuable. PWC’s predictions that the pharmaceutical and life sciences sectors will see increased M&A activity in 2024, and its estimation that cumulative deal value in the industry could reach $250 billion, may be on target. That would be a nice improvement from 2023’s total of less than half of that ($128.8 billion across 112 acquisitions). https://lnkd.in/eX3FJ56Q

🧬 The BioTech $100-billion Club 🧬 While the biotech industry has been faced difficultly in recent times, upward trajectory is back on the horizon. Numerous big biotech names have been able to capitalise on their landmark products to launch new innovative projects. Faced with financial challenges, the leaders of the industry have been able to adapt to the changing dynamics of the market. At a time when the industry is set to recover, the companies in this list will play an important role in the developments of this year and beyond. Heres an quick overview of some top BioTech companies leading the way with over 100 billion market cap behind them 👉 1 - Eli Lilly and Company – $717 billion 2 - Novo Nordisk – $561 billion 3 - Johnson & Johnson – $389 billion 4 - Merck Group – $322 billion 5 - AbbVie – $314 billion 6 - Novartis – $205 billion 7 - AstraZeneca – $196 billion 8 - Roche – $190 billion 9 - Pfizer – $150 billion 10 - Amgen – $148 billion 11 - Vertex Pharmaceuticals – $112 billion 12 - Sanofi – $110 billion 13 - Regeneron – $108 billion 14 - Bristol Myers Squibb – $102 billion #BioTech #biotechnology #marketcapitalization #pharma https://lnkd.in/ekPGyC2u

AbbVie #Strategic #Acquisition of Landos Biopharma, Inc.: Strengthening the #Anti-#Inflammatory #Pipeline (Potential $212M Deal) Here is the #QuickSummary 1. #StrategicAcquisition Move: AbbVie, amid the pressure on its blockbuster drug #Humira from biosimilars, has strategically acquired Landos Biopharma, further solidifying its stance in the #antiinflammatory therapeutics market. 2. #FinancialTransaction Details: AbbVie's acquisition involves a significant investment of $20.42 per share, totaling approximately $137.5 million in cash for Landos, with potential additional payments of up to $75 million contingent upon meeting specific #clinicalmilestones, underlining AbbVie's commitment to advancing innovative therapies. 3. #EnhancedPortfolio Addition: With the acquisition, AbbVie gains access to Landos' leading asset, NX-13, an oral NLRX1 agonist targeting #ulcerativecolitis (UC) and #Crohnsdisease, boasting an #antiinflammatory mechanism of action coupled with epithelial repair facilitation, pivotal in addressing UC and Crohn's. 4. #MarketLandscape and GrowthStrategy: As AbbVie navigates the competitive landscape, it continues to reinforce its position by diversifying its product offerings and pursuing strategic collaborations, evident in recent partnerships with OSE Immunotherapeutics and Tentarix, aiming to address chronic inflammation and bolster its oncology and immunology pipelines. 5.#StrategicVision Amid Patent Cliff: With Humira facing patent challenges and biosimilar competition, AbbVie's proactive approach through acquisitions and collaborations reflects its commitment to mitigating the impact of the patent cliff, demonstrating a forward-looking strategy to sustain growth and innovation in the #pharmaceuticalindustry. AbbVie Landos Biopharma, Inc. -PP Prathyusha Pitta. Ph.D., MBA #PPInsights #AbbVie #LandosBiopharma #AutoimmuneTreatment #TherapeuticInnovation #Pharmaceuticals #ClinicalTrials #Biopharmaceuticals #InflammatoryDiseases #UlcerativeColitis #CrohnsDisease #NLRX1Agonist #DrugDevelopment #MedicalResearch #HealthcareAdvancements #Biotech #DrugPipeline #TherapeuticProgress #MedicalBreakthroughs #TreatmentAdvancements #InnovationInHealthcare #PatientCare #HealthcareInvestment #TherapeuticDiscovery #InnovativeMedicine #ClinicalInnovation #MedicalAdvances #ImmunologyResearch #BiomedicalAdvancements #PharmaResearch #BiotechInnovation #MedicalDiscovery #PrathyushaPitta #WomenInConsulting #WomenInPharma #ConsultingInsights #PharmaInsights #WomenLeaders #ConsultingWomen #PharmaWomen #ConsultingLife #WomenEmpowerment #CareerWomen #ConsultingFirm #PharmaceuticalIndustry #ConsultingWorld #ProfessionalWomen #WomenInBusiness #WomenLeadership #ConsultingCareer #PharmaCareer #DiversityInConsulting #DiversityInPharma #WomenInLeadership #ConsultingCommunity For more details : https://lnkd.in/gMpsJ_R8

Stories making headlines today in the biopharma industry: AbbVie's CEO, Rick Gonzalez, is set to retire in July, handing over to Robert Michael, the firm's current president and chief operating officer. This transition, following Gonzalez's successful stewardship over top-selling drug, Humira, presents a unique scenario in a sector known for favoring external hires for leadership roles. In other pharma news, giants Bristol Myers Squibb, Novartis, Novo Nordisk, and J&J’s Janssen are collectively challenging laws under the Inflation Reduction Act in court, while Bayer's CEO Bill Anderson is set to cut dividends by a staggering 95% in an ambitious turnaround effort. Sanofi's Genzyme is facing a revived lawsuit over access to its Fabry disease drug, while Takeda takes on a new corporate restructuring phase to raise its US profile. Meanwhile, a Chinese API manufacturer faces stern warnings over QC concerns from the FDA. Resilience is investing a significant $225M to widen its manufacturing capacity in Cincinnati, while WuXi AppTec's US subsidiary will handle manufacturing of Iovance’s TIL Therapy. In late-stage clinical trial findings, AstraZeneca’s drug, Tagrisso, showed promise in lung cancer treatment, reshuffling the biotech's $100 billion club. Furthermore, FDA has approved Iovance's novel cell therapy for melanoma, the first of its kind based on tumor-infiltrating lymphocytes, marking another giant leap for cancer therapeutics. #pharma #biotech #topstories #biodatastudio

🔬 November Pharma Industry Updates: Layoffs, Funding, Acquisitions, and More! 💊 The pharma industry is constantly evolving, and November 2023 was no exception. Here's a roundup of the latest updates, including layoffs, funding, acquisitions, and clinical trial results. 🧪 𝐋𝐚𝐲𝐨𝐟𝐟𝐬 💔 Biotech layoffs continue in November: Seres Therapeutics, Kronos Bio, Rani Therapeutics, Sangamo Therapeutics, Inc., Galapagos, and Locanabio, Inc. 👋 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 💰 Abingworth secures $356M for late-stage drug development. 🎯 Bioluminescence Ventures launches with $477M to accelerate drug discovery in precision and cell/gene therapy. 🔬🧬 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧𝐬 🤝 Novartis acquires Chinook Therapeutics, a Novartis Company for over $3 billion. 💊💉 United Therapeutics Corporation announces acquisition of Miromatrix Medical Inc. 🧬 Eli Lilly and Company collaborates with Beam Therapeutics in a $250 million deal for gene editing in heart disease. ❤️🩺 AstraZeneca signs gene-editing deal with Cellectis. 🧬🤝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 🧪 Novartis announces positive Phase 3 data from acquired Chinook Therapeutics, a Novartis Company drug candidate. 💊👍 Sanofi invests in MeiraGTx's gene-regulating technology. 🧬🧪 MapLight Therapeutics, Inc. raises $225M for schizophrenia and Parkinson’s drug development. 🧠💊 PHARNEXT receives a non-binding 510 million € offer for PXT3003, a treatment for Charcot-Marie-Tooth disease. 🦵🦶 bluebird bio agrees to sell FDA priority review voucher for $103 million. 📑💉 𝐎𝐭𝐡𝐞𝐫 𝐍𝐞𝐰𝐬 📰 Novo Nordisk and Eli Lilly and Company report strong sales for GLP-1 drugs. 📈💰 BioMarin Pharmaceutical Inc. names Genentech veteran Alexander Hardy as new CEO. 👨⚕️🧬 Pfizer reports first quarterly loss since 2019. 📉😭 Novo Nordisk ramps up Wegovy® production with FUJIFILM Diosynth Biotechnologies contract. 💉🚚 Bristol Myers Squibb elects Chris Boerner as new board chairman. 🏢💼 Nanobiotix raises 51.5 million € for phase III cancer treatment study and overall R&D. 🔬🧬 Moderna expects yearly sales at the lower end of forecast. 📉💰 #pharma #biotech #drugdiscovery #clinicaltrials

Regeneron and Vertex Pharmaceuticals crossed the USD100 bn market threshold. In comparaison GSK market cap is now c.USD 85bn and Bristol Myers Squibb slipped below the USD $100 bn after earnings release (first time since 2019). Lessons learned. - They joined about 15 other #drugmakers giants like Johnson & Johnson, Merck, Novartis, Eli Lilly and Company, Novo Nordisk, AbbVie, Roche... - Even if this is "just" symbolic, it also sign of #healthcare industry evolution. The two #biotechs that have spent years building their R&D identities with a sharper scientific focus and far less #dealmaking than typically seen in pharma industry. It’s a sign that new approaches to #mergersandacquisitions, R&D and leadership strategies are shaping the future of pharma, and how the newest giants have been built differently (while many older members of the $100 billion club have been doing large, late-stage deals, the newest inductees rarely do). - Vertex and Regeneron have bought #biotechs on the relative cheap to bring in long-term science, rather than targeting near-term revenue, such as Vertex’s $950 million acquisition of #Semmatherapeutics in 2019 around its #diabetes #celltherapy research, or Regeneron scooping up the gene therapy biotech Decibel Therapeutics last year for $109 million. - Does it mean that majority of M&A destroys shareholder value? For example at the time when Bristol Myers Squibb acquired Celgene (USD 74bn) the deal was driven by need to maintain growth which has been the case for a while. But now the new #generic competition to Celgene’s best-selling REVLIMID is a problem. And the problem remains with the massive #patent cliff with OPDIVO® (nivolumab) US HCP and #eliquis (BMS agreed to acquire Karuna Therapeutics and RayzeBio late 2023) and the stock down 30% over the last year. - Does it mean that it is not just because you have a hole in your pipeline that it doesn’t necessarily mean the right answer is to do M&A on a Phase III product? - Does it mean that long standing leadership is an advantage? #lenSchleifer and george yancopoulos, have been Regeneron’s CEO-CSO duo for 35 years. Vertex has enjoyed a smooth handoff after #JeffreyLeiden to Reshma Kewalramani, MD FASN. This enabled Regeneron to build an #ophthalmology franchise with #blockbuster Eylea US, EyePoint Pharmaceuticals, 4D Molecular Therapeutics and Adverum Biotechnologies - Does it mean that this is definitive ? For sure, no ! Eli Lilly and Company market cap felt below USD 30bn in early 2010s. Now it is more c. USD750bn Natixis Corporate & Investment Banking #healthcaresector #biotechnologyindustry #bigpharma #patentcliff #healthcareindustry #biotechnology  

JUST IN: Biopharmaceutical company Apollo Therapeutics raises $226.5m in their Series C fundraise, led by Patient Square Capital to develop new medicines with universities. The company was founded in 2015 by a consortium of tech transfer offices and pharma companies to turn basic university research into medicines, prior to a management buy-out in 2021. Imperial continues to be one of Apollo’s major partners on programmes including vaccines to prevent exacerbations of asthma and COPD, cancer treatment, and a treatment for pulmonary arterial hypertension. “Apollo’s new funding is great news for pharmaceutical innovation in the UK. It’s also a vote of confidence in Imperial and other UK universities, and reflects the moves we are making to build ever more fruitful partnerships with investors and businesses in order to accelerate the translation of research breakthroughs into new medical treatments that improve patients’ lives.” said Dr Simon Hepworth, Imperial's Director of Enterprise. Dr Vjera Magdalenic-Moussavi, Director of Industry Partnerships and Commercialisation (Medicine) at Imperial, added: "It's fantastic to see insights from the basic research taking place at Imperial turning into potentially life-changing new treatments, and we're grateful to Apollo for taking these journeys with us – my congratulations to the team on their major new funding." Read more here- https://hubs.ly/Q021fQwm0 #Therapeutics #Medicine #Fundraise #SeriesC #Research #Funding #Enterprise #Imperial